Download week4: annotated bibliography

Capstone
WEEK4: ANNOTATED BIBLIOGRAPHY
1) Ye, L., Chang, J. C., Lin, C., Sun, X., Yu, J., & Kan, Y. W. (2009). Induced
pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell
anemia and option in prenatal diagnosis in genetic diseases. Proceedings of the
National Academy of Sciences, 106(24), 9826-9830.
Ye, Lin, studied about the prenatal diagnosis of hereditary diseases like sickle cell disease and
their treat by inducing pluripotent stem cells and gene therapy. Their paper published in 2009 in
Proceedings of the National Academy of Sciences. The development of reprogramming somatic
cells to induced pluripotent stem cells gives a conceivable new way to treat sickle cell sickness.
Induced pluripotent stem (iPS) cells can be produced using these patients' somatic cells and the
change in the beta-globin gene rectified by gene targeting, and the cells developed into
hematopoietic cells to be come back to the patient.
2) Pearson, E. G., & Flake, A. W. (2013, February). Stem cell and genetic therapies for
the fetus. In Seminars in pediatric surgery (Vol. 22, No. 1, pp. 56-61). WB Saunders.
Pearson, E. G., & Flake, A. W. describes about the stem cell and gene therapy for the fetus in
their paper. Both of these technologies are very important for the treatment of sickle cell disease.
The pre-birth determination and management of congenital sickness has gained huge ground
over the earlier decade. At present, fetal treatment gives remedial choices to a scope of inborn
disorders like sickle cell anemia; however, it is confined to the treatment of fetal
pathophysiology. Betterment in pre-birth screening and the early finding of hereditary diseases
like sickle cell anemia take into account preemptive treatment of foreseen postnatal infection by
gene therapy and stem cell therapy.
3) Sebastiano, V., Maeder, M. L., Angstman, J. F., Haddad, B., Khayter, C., Yeo, D. T.
& Joung, J. K. (2011). In situ genetic correction of the sickle cell anemia mutation in
human induced pluripotent stem cells using engineered zinc finger nucleases. Stem
Cells, 29(11), 1717-1726.
Sebastiano, V. explains about the benefits of zinc fingers in human gene correction in sickle cell
disease. Zinc fingers are the modern technology used in the correction of defective gene in sickle
cell disease. Recently, engineered zinc finger nucleases (ZFNs) have been appeared to
generously expand HR frequencies in human iPSCs (induced pleuripotent stem cell), raising the
possibility of utilizing this innovation to cure disease-causing mutations. Here, they depict the
generation of iPSC lines (induced pleuripotent stem cell) from sickle cell anemia patients and in
situ treatment of the disease bringing on change utilizing three ZFN pairs made by the freely
accessible oligomerized pool engineering method.